Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD (4502)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 758 B
EBIT 2018 -
Net income 2018 168 B
Debt 2018 724 B
Yield 2018 3,06%
Sales 2019 1 774 B
EBIT 2019 -
Net income 2019 153 B
Debt 2019 656 B
Yield 2019 3,06%
P/E ratio 2018 26,97
P/E ratio 2019 28,89
EV / Sales2018 3,06x
EV / Sales2019 2,99x
Capitalization 4 656 B
More Financials
Company
Takeda Pharmaceutical Co., Ltd. is a research-based global pharmaceutical company that engages in the manufacture, sale, import, export, and marketing of pharmaceutical drugs.It operates through the following segments: Ethical Drug, Consumer Healthcare, and Others.The Ethical Drugs segment includes... 
More about the company
Surperformance© ratings of Takeda Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on TAKEDA PHARMACEUTICAL CO L
02/23TAKEDA PHARMACEUTICAL : Patent Issued for Multiple PPI Dosage Form (USPTO 988915..
AQ
02/23TAKEDA PHARMACEUTICAL : Announces Its Certification in Select Group of Global To..
AQ
02/22TAKEDA PHARMACEUTICAL : Sustainable Value Report 2017 Receives Excellence Award ..
AQ
02/22TAKEDA PHARMACEUTICAL : Fred Hutch, UW Medicine Alliance With Takeda to Advance ..
AQ
02/21TAKEDA PHARMACEUTICAL : Wave Life Sciences and Takeda Form Global Strategic Coll..
AQ
02/21TAKEDA PHARMACEUTICAL : Organ-on-chip company Emulate reveals new deals
AQ
02/21TAKEDA PHARMACEUTICAL : Wave in CNS nucleic acid deal
AQ
02/20TAKEDA PHARMACEUTICAL : Wave Life Sciences and Takeda Form Global Strategic Coll..
AQ
02/20TAKEDA PHARMACEUTICAL LIMITE : Takeda Pharmaceutical Company Limited
AQ
02/20TAKEDA PHARMACEUTICAL : Deepens Commitment to Develop Innovative Treatments for ..
BU
More news
Sector news : Pharmaceuticals - NEC
02/23PUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
02/23SANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/23SHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
02/23NOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
02/20$WVE: WAVE Life Sciences forms global strategic collaboration with Takeda Pha.. 
02/15Takeda Announces Its Certification in Select Group of Global Top Employers® 2.. 
02/01Takeda Pharmaceutical : Japan's Takeda third quarter profit jumps almost 60 p.. 
02/01Takeda Reports 3rd Quarter FY2017 Results: OSAKA, Japan--(BUSINESS WIRE)--Tak.. 
02/01Takeda Pharmaceutical : Reports 3rd Quarter FY2017 Results  
More tweets
Qtime:28
News from SeekingAlpha
02/21YOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
02/20Wave Life Sciences teams up with Takeda to develop CNS treatments 
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease 
02/08Pluristem - Hidden Treasures And Sudden Catalysts 
02/07Britain's NHS advisor NICE on board with Takeda's Ninlaro for multiple myelom.. 
Chart TAKEDA PHARMACEUTICAL CO L
Duration : Period :
Takeda Pharmaceutical Co L Technical Analysis Chart | 4502 | JP3463000004 | 4-Traders
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 6 723  JPY
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
James Kehoe Director, Chief Financial & Corporate Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Shinji Ninomiya Manager-Research & Development
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD-8.37%43 574
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618